3033865-40-3
Chemical Structure
DOTA Conjugated JM#21 derivative 7
- CAS No.: 3033865-40-3
- Formula:C66H114N22O16
- Molecular Weight:1471.75
InChIKey: IOKNMYWBFSAUHS-AHVIHFTKSA-N
SMILES: O=C([C@H](N)[C@@H](CC)C)N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N)=O)CCCCNC(CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1)=O)=O)CCCCN)=O)CCCNC(N)=N)=O)CO)=O)CC2=CNC3=CC=CC=C23)=O)CCCNC(N)=N)=O)CC(C)C
Biological Activity: DOTA Conjugated JM#21 derivative 7 (compound Ligand-7) is a derivative of CXCR4 targeting peptide conjugated with DOTA and can be used to produce radioligands. Radiolabeled DOTA Conjugated JM#21 derivative 7, i.e., 177Lu-DOTA, has excellent CXCR4 tumor targeting. In vitro biodistribution results of 177Lu-DOTA showed very low uptake in all non-targeted organs except kidney[1]. DOTA Conjugated JM#21 derivative 7 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
DOTA Conjugated JM#21 derivative 7 | DOTA Conjugated JM#21 derivative 7 (compound Ligand-7) is a derivative of CXCR4 targeting peptide conjugated with DOTA and can be used to produce radioligands. Radiolabeled DOTA Conjugated JM#21 derivative 7, i.e., 177Lu-DOTA, has excellent CXCR4 tumor targeting. In vitro biodistribution results of 177Lu-DOTA showed very low uptake in all non-targeted organs except kidney. DOTA Conjugated JM#21 derivative 7 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
